Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages 1100-1106

  Stolk, Roeland F ^a   Bakx, Carel ^a   Mulder, Jan ^a   Timmers, Henri J L M ^a   Lenders, Jacques W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHYPERTENSIVE AGENT; CATECHOLAMINE; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADRENALIN URINE LEVEL; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NORADRENALIN BLOOD LEVEL; NORADRENALIN URINE LEVEL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CASE-CONTROL STUDIES; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MORBIDITY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NOREPINEPHRINE; PHEOCHROMOCYTOMA; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84874863067     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3669     Document Type: Article

References (33)

1. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12:609-615. (Pubitemid 24192887)
2. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147:1289-1293.
3. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med. 2000;30:648-652. (Pubitemid 32055962)
4. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-675. (Pubitemid 41176020)
5. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29:2049-2060.
6. Manger WM, Gifford RW. The Clinical and Experimental Pheochromocytoma. 2nd ed. Malden, MA: Blackwell Science; 1996.
7. Brouwers FM, Eisenhofer G, Lenders JW, Pacak K. Emergencies caused by pheochromocytoma, neuroblastoma or ganglioneuroma. Endocrinol Metab Clin North Am. 2006;35:699-724. (Pubitemid 44810888)
8. Timmers HJ, Brouwers FM, Hermus AR, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. 2008;15:1127-1133.
9. Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Tisell LE, Ahlman H. Mortality associated with pheochromocytoma: increased risk for additional tumors. Ann N Y Acad Sci. 2006;1073: 444-448. (Pubitemid 44912039)
10. Amar L, Servais A, Gimenez-Roqueplo A, Zinzindohoue F, Chatellier G, Plouin P. Year of diagnosis, features at presentation and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90:2110-2116. (Pubitemid 40586247)
11. Liao WB, Liu CF, Chiang CW, Kung CT, Lee CW. Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med. 2000;18: 622-625.
12. Walma EP, Thomas S, Prins A, Grundmeyer HG, van der Laan JR, Wiersma TJ. NHG-standaard Hypertensie (3e herziening). Huisarts Wet. 2003;46:435-449.
13. van der Wel M, Bakx C, de Grauw W, van Gerwen W, Mulder J, van Weel C. The influence of guideline revisions on the process and outcome of hypertension management in general practice: a descriptive study. Eur J Gen Pract. 2008;1:47-52.
14. Tsujimoto G, Manger WM, Hoffman BB. Desensitization of betaadrenergic receptors by pheochromocytoma. Endocrinology. 1984;114:1272-1278.
15. Zelinka T, Strauch B, Petrák O, et al. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens. 2005;23:2033-2039. (Pubitemid 41830399)
16. Nestler JE, McClanahan MA. Diabetes and adrenal disease. Baillieres Clin Endocrinol Metab. 1992;6:829-847.
17. Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stressinduced heart disease. Can J Physiol Pharmacol. 2009;87:493-514.
18. Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fundam Clin Pharmacol. 2010;24:539-546.
19. James TN. De subitaneis mortibus. XIX On the cause of sudden death in pheochromocytoma, with special reference to the pulmonary arteries, the cardiac conduction system, and the aggregation of platelets. Circulation. 1976;54:348-356.
20. Banga HS, Simons ER, Brass LF, Rittenhouse SE. Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine. Proc Natl Acad Sci U S A. 1986;83:9197-9201. (Pubitemid 17223562)
21. Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996;26:353-370. (Pubitemid 26171949)
22. Pauletto P, Scannapieco G, Pessina AC. Sympathetic drive and vascular damage in hypertension and atherosclerosis. Hypertension. 1991;17:III75-III81.
23. Pettersson K, Bejne B, Bjork H, Strawn WB, Bondjers G. Experimental sympathetic activation causes endothelial injury in the rabbit thoracic aorta via beta 1-adrenoceptor activation. Circ Res. 1990;67:1027-1034. (Pubitemid 20315034)
24. Vatner SF, Higgins CB, Braunwald E. Effects of norepinephrine on coronary circulation and left ventricular dynamics in the conscious dog. Circ Res. 1974;34:812-823.
25. Ablad B, Bjorkman JA, Gustafsson D, Hansson G, Ostlund-Lindqvist AM, Pettersson K. The role of sympathetic activity in atherogenesis: effects of beta-blockade. Am Heart J. 1988;116:322-327.
26. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572-577. (Pubitemid 34123409)
27. Ueda N, Satoh S, Kuroiwa Y. Multiple cerebral infarction and cardiomyopathy with pheochromocytoma. Neurologist. 2011;17:34-37.
28. Razavi M, Bendixen B, Maley JE, et al. CNS pseudovasculitis in a patient with pheochromocytoma. Neurology. 1999;52:1088-1090. (Pubitemid 29161630)
29. Dagartzikas MI, Sprague K, Carter G, Tobias JD. Cerebrovascular event, dilated cardiomyopathy, and pheochromocytoma. Pediatr Emerg Care. 2002;18:33-35. (Pubitemid 34174343)
30. Lutchman D, Buchholz S, Keightley C. Phaeochromocytoma-associated critical peripheral ischaemia. Intern Med J. 2010;40:150-153.
31. Tan F, Thai AC, Cheah WK, Mukherjee JJ. Unusual presentation of pheochromocytoma with ischemic sigmoid colitis and stenosis. South Med J. 2009;102:1068-1070.
32. Szmulowicz UM, Savoie LM. Ischemic colitis: an uncommon manifestation of pheochromocytoma. Am Surg. 2007;73:400-403. (Pubitemid 351396688)
33. Eisenhofer G, Timmers HJ, Lenders JW, et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab. 2011;96:375-384.